Immuron (IMRN) Retained Earnings (2016 - 2025)
Immuron (IMRN) posted quarterly Retained Earnings of -$824804.3 for Q3 2025, down 4.45% year-over-year from -$863193.9 in Q3 2024, and up 98.44% quarter-over-quarter from -$52.8 million in Q2 2025.
Immuron (IMRN) Retained Earnings (2016 - 2025) Analysis & Trends
Immuron's Retained Earnings history runs 10 years deep, the most recent figure standing at -$824804.3 for Q3 2025.
- In Q3 2025, Retained Earnings fell 4.45% year-over-year to -$824804.3; the TTM figure through Sep 2025 stood at -$824804.3 (down 4.45% YoY), while the FY2025 annual figure was -$824804.3, down 4.45% from the prior year.
- Retained Earnings for Q3 2025 stood at -$824804.3, up from -$52.8 million in the prior quarter.
- The five-year high for Retained Earnings was $88.4 million in Q2 2023, with the low at -$52.8 million in Q2 2025.
- The 5-year median for Retained Earnings is -$47.4 million (2023), against an average of -$25.7 million.
- The sharpest annual moves came in 2023 and 2024: Retained Earnings surged 280.44% in 2023, then slumped 10808.63% in 2024.
- Immuron's Retained Earnings stood at -$48.3 million in 2021, then advanced by 6.85% to -$45.0 million in 2022, then surged by 98.93% to -$482570.0 in 2023, then plunged by 10808.63% to -$52.6 million in 2024, then soared by 98.43% to -$824804.3 in 2025.
- Business Quant data shows IMRN's Retained Earnings at -$824804.3 in Q3 2025, -$52.8 million in Q2 2025, and -$52.6 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Immuron | 6.75 Mn | 6.73 Mn | - | -824,804.27 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 2, 2025 | -824,804.27 |
| Jun 30, 2025 | -52.80 Mn |
| Dec 31, 2024 | -52.64 Mn |
| Sep 9, 2024 | -789,683.96 |
| Jun 30, 2024 | -52.04 Mn |
| Dec 31, 2023 | -482,569.99 |
| Sep 28, 2023 | -47.23 Mn |
| Aug 30, 2023 | -720,553.96 |
| Jun 30, 2023 | 88.44 Mn |
| Dec 31, 2022 | -44.96 Mn |
| Aug 31, 2022 | -47.58 Mn |
| Jun 30, 2022 | -49.01 Mn |
| Dec 31, 2021 | -48.26 Mn |
| Jun 30, 2021 | -50.77 Mn |
| Dec 31, 2020 | -632,871.95 |
| Sep 1, 2020 | -57.92 Mn |
| Jun 30, 2020 | -37.96 Mn |
| Dec 31, 2019 | -579,164.23 |
| Jun 30, 2019 | 3.01 Mn |
| Dec 31, 2018 | -52.54 Mn |